Gonadal disorders

Growth Disorders, Second Edition

Volumn , Issue , 2007, Pages 472-480

  Ahmed, S Faisal ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548438022     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (87)

1. Hochberg Z. Endocrine Control of Skeletal Maturation: Annotation to Bone Age Readings. Basel: Karger AG, 2002.
2. Laron Z, Sarel R, Pertzelan A. Puberty in Laron type dwarfism. Eur J Pediatr 1980; 134: 79–83.
3. Tanaka T, Cohen P, Clayton PE, et al. Diagnosis and management of growth hormone deficiency in childhood and adolescence – part 2: growth hormone treatment in growth hormone deficient children. Growth Horm IGF Res 2002; 12: 323–41.
4. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000; 25: 1–16.
5. Simpson E, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000; 11: 184–8.
6. Van Der Eerden BC, Van De Ven J, Lowik CW, et al. Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology 2002; 143: 4048–55.
7. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25: 389–425.
8. Blanchard O, Tsagris L, Rappaport R, et al. Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991; 40: 711–6.
9. Krohn K, Haffner D, Hugel U, et al. 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 2003; 73: 400–10.
10. Frank GR. Role of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol 2003; 41: 217–21.
11. Weise MS, De-Levi KM, Barnes RI, et al. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001; 98: 6871–6.
12. Parfitt MM. Misconceptions (1): Epiphyseal fusion causes cessation of growth. Bone 2002; 30: 337–9.
13. Chowen JA, Frago LM, Argente J. The regulation of GH secretion by sex steroids. Eur J Endocrinol 2004; 151(Suppl 3): U95–100.
14. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744–52.
15. Martha PM Jr., Gorman KM, Blizzard RM, et al. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992; 74: 336–44.
16. Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991; 73: 428–35.
17. Albertsson-Wikland K, Rosberg S, Karlberg J, Groth T. Analysis of 24-hour growth hormone profiles in healthy boys and girls of normal stature: relation to puberty. J Clin Endocrinol Metab 1994; 78: 1195–201.
18. Ulloa-Aguirre A, Blizzard RM, Garcia-Rubi E, et al. Testosterone and oxandrolone, a nonaromatizable androgen, specifically amplify the mass and rate of growth hormone (GH) secreted per burst without altering GH secretory burst duration or frequency or the GH half-life. J Clin Endocrinol Metab 1990; 71: 846–54.
19. Malhotra A, Poon E, Tse WY, et al. The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty. Clin Endocrinol (Oxf) 1993; 38: 393–8.
20. Crowne EC, Wallace WH, Moore C, et al. Effect of low dose oxandrolone and testosterone treatment on the pituitarytesticular and GH axes in boys with constitutional delay of growth and puberty. Clin Endocrinol (Oxf) 1997; 46: 209–16.
21. Eakman GD, Dallas JS, Ponder SW, Keenan BS. The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion. J Clin Endocrinol Metab 1996; 81: 1217–23.
22. Keenan BS, Richards GE, Ponder SW, et al. Androgenstimulated pubertal growth: The effect of testosterone and dihydrotestosterone on GH and IGF-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993; 76: 996–1001.
23. Vanderschueren D, Van Herck E, Suiker AM, et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 1993; 8: 801–9.
24. Martha PM Jr., Rogol AD, Veldhuis JD, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989; 69: 563–70.
25. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64: 51–8.
26. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004; 25: 693–721.
27. Coutant R, de Casson FB, Rouleau S, et al. Divergent effect of endogenous and exogenous sex steroids on the insulinlike growth factor I response to growth hormone in short normal adolescents J Clin Endocrinol Metab 2004; 89: 6185–92.
28. Zachmann M, Prader A, Sobel EH, et al. Pubertal growth in patients with androgen insensitivity: Indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986; 108: 694–7.
29. Marin G, Domené HM, Barnes KM, et al. The effects of estrogen priming and puberty on the growth hormone response to standardized tread-mill exercise and arginineinsulin in normal girls and boys. J Clin Endocrinol Metab 1994; 79: 537–41.
30. Metzger DL, Kerrigan JR. Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. J Clin Endocrinol Metab 1994; 79: 513–8.
31. Veldhuis JD, Metzger DL, Martha PM Jr., et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sexsteroid hormone replacement. J Clin Endocrinol Metab 1997; 82: 3414–20.
32. Metzger DL, Kerrigan JR. Androgen receptor blockade with flutamide enhances growth hormone secretion in late pubertal males: evidence for independent actions of estrogen and androgen. J Clin Endocrinol Metab 1993; 76: 1147–52.
33. Vidal O, Lindberg M, Savendahl L, et al. Disproportional body growth in female estrogen receptor-alphainactivated mice. Biochem Biophys Res Commun 1999; 265: 569–71.
34. Lindberg MK, Alatalo SL, Halleen JM, et al. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol 2001; 171: 229–36.
35. Chagin AS, Lindberg MK, Andersson N, et al. Estrogen receptor-beta inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res 2004; 19: 72–7.
36. Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 2004; 150: 481–7.
37. Svan H, Ritzén EM, Hall K, et al. Estrogens treatment of tall girls: Dose dependency of effects on subsequent growth and IGF-I levels in blood. Acta Paediatr Scand 1991; 80: 328–32.
38. Smith E. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. New Engl J Med 1994; 331: 1056–61.
39. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–98.
40. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics 1997, 99: 505–12.
41. Kaplowitz PB, Oberfield SE, and The Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society: Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Pediatrics 1999, 104: 936–41.
42. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 2003; 24: 668–93.
43. van Winter JT, Noller KL, Zimmerman D, Melton LJ. Natural history of premature thelarche in Olmsted County, Minnesota, 1940 to 1984. J Pediatr 1990; 116: 278–80.
44. Salardi, Cacciari E, Mainetti B, et al. Outcome of premature thelarche: relation to puberty and final height. Arch Dis Child 1998; 79: 173–4.
45. Fontoura M, Brauner R, Prevot C, Rappaport R. Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 1989; 64: 1170–6.
46. Stanhope R, Brook CGD. Thelarche variant: a new syndrome of precocious sexual maturation? Acta Endocrinol (Copenh) 1990; 123: 481–6.
47. Volta C, Bernasconi S, Cisternino M, et al. Isolated premature thelarche and thelarche variant: clinical and auxological follow-up of 119 girls. J Endocrinol Invest 1998; 21: 180–3.
48. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999, 84: 415–23.
49. Saggese G, Ghirri P, Del Vecchio A, et al. Gonadotropin pulsatile secretion in girls with premature menarche. Horm Res 1990; 33: 5–10.
50. Ghizzoni L, Milani S. The natural history of premature adrenarche. J Pediatr Endocrinol Metab 2000; 13(Suppl 5): 1247–51.
51. Pere A, Perheentupa J, Peter M, Voutilainen R. Follow up of growth and steroids in premature adrenarche. Eur J Pediatr 1995; 154: 346–52.
52. Kletter GB, Kelch RP. Effects of gonadotropin-releasing hormone analogue therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994; 79: 331–4.
53. Oerter Klein K. Precocious puberty: Who has it? Who should be treated? [Editorial]. J Clin Endocrinol Metab 1999; 84: 411–4.
54. Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: Accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001; 86: 4127–32.
55. Kreiter M, Burstein S, Rosenfield RL, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990; 117: 364–70.
56. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002; 56: 129–48.
57. Pringle PJ, Stanhope R, Hindmarsh P, Brook CGD. Abnormal pubertal development in primary hypothyroidism. Clin Endocrinol 1988; 28: 479–86.
58. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropinindependent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormonereleasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab 1983; 57: 571–9. 59.
59. Weise M, Flor A, Barnes KM, et al. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J Clin Endocrinol Metab 2004; 89: 103–7.
60. Partsch CJ, Krone N, Riepe FG, et al. Long-term follow-up of spontaneous development in a boy with familial male precocious puberty. Horm Res 2004; 62: 177–81.
61. Stratakis CA, Batista D, Sabnis G, Brodie A. Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome. Clin Endocrinol 2004; 61: 779–80.
62. Sher ES, Migeon CJ, Berkovitz GD. Evaluation of boys with marked breast development at puberty. Clin Pediatr 1998; 37: 367–71.
63. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L. Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol 2004; 61: 55–60.
64. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348: 1855–65.
65. Hemsell DL, Edman CD, Marks JF, et al. Massive extranglandular aromatization of plasma androstenedione resulting in feminization of a prepubertal boy. J Clin Invest 1977; 60: 455–64.
66. Albanese A, Stanhope R. Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995; 126: 545–50.
67. Crowne EC, Shalet SM, Wallace WH, et al. Final height in girls with untreated constitutional delay in growth and puberty. Eur J Pediatr 1991; 150: 708–12.
68. Sperlich M, Butenandt O, Schwarz HP. Final height and predicted height in boys with untreated constitutional growth delay. Eur J Pediatr 1995; 154: 627–32.
69. Baum WF, Schneyer U, Lantzsch AM, Kloditz E. Delay of growth and development in children with bronchial asthma, atopic dermatitis and allergic rhinitis. Exp Clin Endocrinol Diabetes 2002; 110: 53–9.
70. Kelly BP, Paterson WF, Donaldson MD. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months. Clin Endocrinol 2003; 58: 267–72.
71. Pozo J, Argente J. Ascertainment and treatment of delayed puberty. Horm Res 2003; 60(Suppl 3): 35–48.
72. Wickman S, Sipila I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357: 1743–8.
73. Pozo J, Argente J. Delayed puberty in chronic illness. Best Pract Res Clin Endocrinol Metab 2002; 16: 73–90.
74. Alemzadeh N, Rekers-Mombarg LT, Mearin ML, et al. Adult height in patients with early onset of Crohn’s disease. Gut 2002; 51: 26–9.
75. Sawczenko A, Ballinger AB, Croft NM, et al. Adult height in patients with early onset of Crohn’s disease. Gut 2003; 52: 454–5.
76. Karlberg J. On the construction of the infancy–childhood–puberty growth standard. Acta Paediatr Scand Suppl 1989; 356: 26–37.
77. van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med 1992; 41: 259–63.
78. Ratcliffe SG, Butler GE, Jones M. Edinburgh study of growth and development of children with sex chromosome abnormalities. IV. Birth Defects 1990; 26: 1–44.
79. Chiarelli F, Giannini C, Mohn A. Growth, growth factors and diabetes. Eur J Endocrinol 2004; 151: 109–17.
80. Meikle AW. The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid 2004; 14(Suppl 1): S17–25.
81. Pantsiouou S, Stanhope R, Uruena M, et al. Growth prognosis and growth after menarche in primary hypothyroidism. Arch Dis Child 1991; 66: 838–40.
82. Styne DM, Grumbach MM, Kaplan SL, et al. Treatment of Cushing’s disease in childhood and adolescence by transsphenoidal microadenomectomy. N Engl J Med 1984; 310: 889–93.
83. Zadik Z, Cooper M, Chen M, Stern N. Cushing’s disease presenting as pubertal arrest. J Pediatr Endocrinol 1993; 6: 201–4.
84. Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF, et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85: 2664–9.
85. Ogata T, Matsuo N. Comparison of adult height between patients with XX and XY gonadal dysgenesis: support for a Y specific growth gene(s). J Med Genet 1992; 29: 539–41.
86. Ogata T, Tomita K, Hida A, et al. Chromosomal localisation of a Y specific growth gene(s). J Med Genet 1995; 32: 572–5.
87. Hibi I, Tanaka T. Hormonal regulation of growth and maturation II. The effect of hormones and postnatal and pubertal growth. Clin Pediatr Endocrinol 1998; 7: 1–11.